ROCURONIUM BROMIDE INJECTION SOLUTION

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Beli Sekarang

Unduh Karakteristik produk (SPC)
05-05-2020

Bahan aktif:

ROCURONIUM BROMIDE

Tersedia dari:

JUNO PHARMACEUTICALS CORP.

Kode ATC:

M03AC09

INN (Nama Internasional):

ROCURONIUM BROMIDE

Dosis:

10MG

Bentuk farmasi:

SOLUTION

Komposisi:

ROCURONIUM BROMIDE 10MG

Rute administrasi :

INTRAVENOUS

Unit dalam paket:

15G/50G

Jenis Resep:

Prescription

Area terapi:

NEUROMUSCULAR BLOCKING AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0126317001; AHFS:

Status otorisasi:

APPROVED

Tanggal Otorisasi:

2020-05-05

Karakteristik produk

                                _PRODUCT MONOGRAPH: Rocuronium Bromide Injection _
Page 1 of 33
PRODUCT MONOGRAPH
Pr
ROCURONIUM BROMIDE INJECTION
10 mg / mL, Solution for Injection, 5 mL vial
Sterile and Preservative Free
Non-depolarizing Skeletal Neuromuscular Blocking Agent
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, Ontario
L5N 2X7
Date of Revision:
May 5, 2020
Submission Control No.: 238579
_PRODUCT MONOGRAPH: Rocuronium Bromide Injection _
Page 2 of 33
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
11
DOSAGE AND ADMINISTRATION
.............................................................................
12
OVERDOSAGE
................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 17
STORAGE AND STABILITY
.........................................................................................
24
SPECIAL HANDLING INSTRUCTIONS
......................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 25
PART II: SCIENTIFIC INFORMATION
..............................................................................
26
PHARMACEUTICAL INFORMATION
.........................
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Karakteristik produk Karakteristik produk Prancis 05-05-2020

Peringatan pencarian terkait dengan produk ini